365 related articles for article (PubMed ID: 35272867)
1. Reality check: Real-world evidence to support therapeutic development in hematologic malignancies.
Derman BA; Belli AJ; Battiwalla M; Hamadani M; Kansagra A; Lazarus HM; Wang CK
Blood Rev; 2022 May; 53():100913. PubMed ID: 35272867
[TBL] [Abstract][Full Text] [Related]
2. Clinical Pharmacology Applications of Real-World Data and Real-World Evidence in Drug Development and Approval-An Industry Perspective.
Zhu R; Vora B; Menon S; Younis I; Dwivedi G; Meng Z; Datta-Mannan A; Manchandani P; Nayak S; Tammara BK; Garhyan P; Iqbal S; Dagenais S; Chanu P; Mukherjee A; Ghobadi C;
Clin Pharmacol Ther; 2023 Oct; 114(4):751-767. PubMed ID: 37393555
[TBL] [Abstract][Full Text] [Related]
3. Trial designs using real-world data: The changing landscape of the regulatory approval process.
Baumfeld Andre E; Reynolds R; Caubel P; Azoulay L; Dreyer NA
Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1201-1212. PubMed ID: 31823482
[TBL] [Abstract][Full Text] [Related]
4. Real-world data: a comprehensive literature review on the barriers, challenges, and opportunities associated with their inclusion in the health technology assessment process.
Zisis K; Pavi E; Geitona M; Athanasakis K
J Pharm Pharm Sci; 2024; 27():12302. PubMed ID: 38481726
[No Abstract] [Full Text] [Related]
5. Real-World Evidence: A Primer.
Dang A
Pharmaceut Med; 2023 Jan; 37(1):25-36. PubMed ID: 36604368
[TBL] [Abstract][Full Text] [Related]
6. Expert survey on real-world data utilization and real-world evidence generation for regulatory decision-making in drug lifecycle in Korea.
Lee H; Ahn HS; Kwon S; Kang HY; Han E
Clin Transl Sci; 2024 Apr; 17(4):e13801. PubMed ID: 38629484
[TBL] [Abstract][Full Text] [Related]
7. Use of real-world evidence in regulatory decisions for rare diseases in the United States-Current status and future directions.
Wu J; Wang C; Toh S; Pisa FE; Bauer L
Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1213-1218. PubMed ID: 32003065
[TBL] [Abstract][Full Text] [Related]
8. A systematic review of real-world evidence (RWE) supportive of new drug and biologic license application approvals in rare diseases.
Vaghela S; Tanni KA; Banerjee G; Sikirica V
Orphanet J Rare Dis; 2024 Mar; 19(1):117. PubMed ID: 38475874
[TBL] [Abstract][Full Text] [Related]
9. Data Governance for Real-World Data Management: A Proposal for a Checklist to Support Decision Making.
Solà-Morales O; Sigurðardóttir K; Akehurst R; Murphy LA; Mestre-Ferrandiz J; Cunningham D; de Pouvourville G
Value Health; 2023 Apr; 26(4S):32-42. PubMed ID: 36870678
[TBL] [Abstract][Full Text] [Related]
10. Maximizing the Value of Real-World Data and Real-World Evidence to Accelerate Healthcare Transformation in China: Summary of External Advisory Committee Meetings.
Sun F; Bedenkov A; Liu BC; Yang J; Xu JF; Ji L; Zhou M; Zhang S; Li X; Song Y; Chen P; Moreno C
Pharmaceut Med; 2024 May; 38(3):157-166. PubMed ID: 38573457
[TBL] [Abstract][Full Text] [Related]
11. Comparison of two assessments of real-world data and real-world evidence for regulatory decision-making.
Yuan L; Rahman M; Concato J
Clin Transl Sci; 2024 Jan; 17(1):e13702. PubMed ID: 38093484
[TBL] [Abstract][Full Text] [Related]
12. Contribution of Real-World Evidence in European Medicines Agency's Regulatory Decision Making.
Bakker E; Plueschke K; Jonker CJ; Kurz X; Starokozhko V; Mol PGM
Clin Pharmacol Ther; 2023 Jan; 113(1):135-151. PubMed ID: 36254408
[TBL] [Abstract][Full Text] [Related]
13. Use of real-world evidence for oncology clinical decision making in emerging economies.
Petracci F; Ghai C; Pangilinan A; Suarez LA; Uehara R; Ghosn M
Future Oncol; 2021 Aug; 17(22):2951-2960. PubMed ID: 34044583
[TBL] [Abstract][Full Text] [Related]
14. Real-world data for health technology assessment for reimbursement decisions in Asia: current landscape and a way forward.
Lou J; Kc S; Toh KY; Dabak S; Adler A; Ahn J; Bayani DBS; Chan K; Choiphel D; Chua B; Genuino AJ; Guerrero AM; Kearney B; Lin LW; Liu Y; Nakamura R; Pearce F; Prinja S; Pwu RF; Shafie AA; Sui B; Suwantika A; Teerawattananon Y; Tunis S; Wu HM; Zalcberg J; Zhao K; Isaranuwatchai W; Wee HL
Int J Technol Assess Health Care; 2020 Oct; 36(5):474-480. PubMed ID: 32928330
[TBL] [Abstract][Full Text] [Related]
15. Current Status, Challenges, and Future Perspectives of Real-World Data and Real-World Evidence in Japan.
Hiramatsu K; Barrett A; Miyata Y;
Drugs Real World Outcomes; 2021 Dec; 8(4):459-480. PubMed ID: 34148219
[TBL] [Abstract][Full Text] [Related]
16. Statistical Considerations on the Use of RWD/RWE for Oncology Drug Approvals: Overview and Lessons Learned.
Ro SK; Zhang W; Jiang Q; Li XN; Liu R; Lu CC; Marchenko O; Sun L; Zhao J
Ther Innov Regul Sci; 2023 Jul; 57(4):899-910. PubMed ID: 37179264
[TBL] [Abstract][Full Text] [Related]
17. Data Science Methods for Real-World Evidence Generation in Real-World Data.
Liu F
Annu Rev Biomed Data Sci; 2024 May; ():. PubMed ID: 38748863
[TBL] [Abstract][Full Text] [Related]
18. Evolving Acceptance and Use of RWE for Regulatory Decision Making on the Benefit/Risk Assessment of a Drug in Japan.
Nishioka K; Makimura T; Ishiguro A; Nonaka T; Yamaguchi M; Uyama Y
Clin Pharmacol Ther; 2022 Jan; 111(1):35-43. PubMed ID: 34528701
[TBL] [Abstract][Full Text] [Related]
19. The Case for Real-world Evidence in the Future of Clinical Research on Chronic Myeloid Leukemia.
Webster J; Smith BD
Clin Ther; 2019 Feb; 41(2):336-349. PubMed ID: 30709609
[TBL] [Abstract][Full Text] [Related]
20. Use of Clinical Data Interchange Standards Consortium (CDISC) Standards for Real-world Data: Expert Perspectives From a Qualitative Delphi Survey.
Facile R; Muhlbradt EE; Gong M; Li Q; Popat V; Pétavy F; Cornet R; Ruan Y; Koide D; Saito TI; Hume S; Rockhold F; Bao W; Dubman S; Jauregui Wurst B
JMIR Med Inform; 2022 Jan; 10(1):e30363. PubMed ID: 35084343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
